More Than One in 10 With Cardiovascular Disease Face Food Insecurity
FRIDAY, Sept. 30, 2022 (HealthDay News) — Food insecurity increased from 1999 through 2018 among patients with cardiovascular disease (CVD), according to a study published online Sept. 28 in JAMA Cardiology.Eric J. Brandt, M.D., from the University o…
Learn MoreMore Than One in 10 With Cardiovascular Disease Face Food Insecurity
FRIDAY, Sept. 30, 2022 (HealthDay News) — Food insecurity increased from 1999 through 2018 among patients with cardiovascular disease (CVD), according to a study published online Sept. 28 in JAMA Cardiology.Eric J. Brandt, M.D., from the University o…
Learn MoreMore Than One in 10 With Cardiovascular Disease Face Food Insecurity
FRIDAY, Sept. 30, 2022 (HealthDay News) — Food insecurity increased from 1999 through 2018 among patients with cardiovascular disease (CVD), according to a study published online Sept. 28 in JAMA Cardiology.Eric J. Brandt, M.D., from the University o…
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn MoreU.S. Will Spend $266 Million to Bolster Public Health Programs
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. government will invest $266 million to shore up the community and public health workforce using American Rescue Plan funding.About $225.5 million will go to 83 recipients to support training and appr…
Learn More